<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025775</url>
  </required_header>
  <id_info>
    <org_study_id>AP-Renal</org_study_id>
    <nct_id>NCT04025775</nct_id>
  </id_info>
  <brief_title>Closed-loop in Adults With T2D Requiring Dialysis</brief_title>
  <acronym>AP-Renal</acronym>
  <official_title>An Open-label, Two-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery in Comparison With Standard Care, in Adults With Type 2 Diabetes Requiring Maintenance Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the efficacy, safety and utility of fully
      automated closed-loop glucose control in the home setting over a 20 day period in adults with
      type 2 diabetes (T2D) requiring maintenance dialysis. This study builds on previous and
      on-going studies of closed-loop systems that have been performed in Cambridge in adults with
      type 1 diabetes in the home setting, and in adults with type 2 diabetes in the inpatient
      setting.

      This is an open-label, two-centre, randomised, cross-over study, involving two home study
      periods during which glucose levels will be controlled either by a fully automated
      closed-loop system or by participants' usual insulin therapy in random order. Each treatment
      arm is 20 days long with a 2-4 week washout period between treatments. A total of up to 40
      adults with T2D requiring maintenance dialysis will be recruited through outpatient clinics
      or the dialysis unit, to allow for 32 completed participants available for assessment.

      Participants will receive appropriate training by the research team on the safe use of the
      study devices (insulin pump and continuous glucose monitoring (CGM) and closed-loop insulin
      delivery system). Participants in the control arm will continue with standard therapy and
      will wear a blinded CGM system.

      The primary outcome is time spent with glucose levels in the target range between 5.6 and
      10.0 mmol/L as recorded by CGM. Secondary outcomes are the time spent with glucose levels
      above and below target, as recorded by CGM, and other CGM-based metrics in addition to
      insulin requirements. Safety evaluation comprises the tabulation of severe hypoglycaemic
      episodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of clinical trial To determine the efficacy, safety and utility of fully automated
      closed-loop insulin delivery in the home setting in adults with type 2 diabetes requiring
      maintenance dialysis.

      Study objectives The study objective is to compare fully automated closed-loop insulin
      delivery with usual care in adults with type 2 diabetes requiring maintenance dialysis.

        1. EFFICACY: The objective is to assess the ability of fully-automated closed-loop insulin
           delivery in maintaining CGM glucose levels within the target range from 5.6 to 10.0
           mmol/l as compared to usual care in adults with type 2 diabetes requiring maintenance
           dialysis.

        2. SAFETY: The objective is to evaluate the safety of fully automated closed-loop insulin
           delivery in terms of episodes and severity of hypoglycaemia, and nature and severity of
           other adverse events.

        3. UTILITY: The objective is to determine the acceptability and duration of use of the
           closed-loop system.

      Study design An open-label, two-centre, randomised, two-period crossover study comparing
      fully automated closed-loop insulin delivery with usual care in adults with type 2 diabetes
      requiring dialysis. Two intervention periods in the home setting will last 20 days each with
      a 2-4 week washout period. The order of the two interventions will be random.

      Study endpoints The primary endpoint is the time spent in the target glucose range from 5.6
      to 10.0 mmol/l based on CGM glucose levels during the 20 day home stay.

      Other key endpoints:

        -  Time spent with sensor glucose above target (10.0 mmol/l)

        -  Time spent with sensor glucose &lt;3.9 mmol/l

        -  Average of sensor glucose levels

      Secondary endpoints include:

        -  Time spent with sensor glucose below target (5.6 mmol/l)

        -  Time spent with sensor glucose &lt;3.0 mmol/l)

        -  Time spent with sensor glucose levels in significant hyperglycaemia (glucose levels &gt; 20
           mmol/l)

        -  Standard deviation and coefficient of variation of sensor glucose levels

        -  AUC of glucose below 3.5 mmol/l (63 mg/dl)

        -  Total daily insulin requirements

        -  Average inter-dialytic weight gain

      Safety evaluation Assessment of frequency and severity of hypoglycaemic episodes and nature
      and severity of other adverse events.

      Utility evaluation Assessment of the acceptability and duration of use of the closed-loop
      system.

      Participating clinical centres

      UK 1. Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge,

      Switzerland

      1. Bern University Hospital, Bern

      Sample size 32 adults completing the study. Recruitment will target up to 40 adults to allow
      for drop-outs.

      Maximum duration of study for a participant 12 weeks

      Recruitment Participants will be recruited through the adult diabetes outpatient clinics or
      dialysis units at participating centres.

      Consent Written informed consent will be obtained from participants according to Research
      Ethics Committee (REC) requirements.

      Screening and baseline assessment Eligible participants will undergo a baseline evaluation
      including medical (diabetes) history and current therapy.

      Randomisation Eligible participants will be randomised in a 1:1 ratio using randomisation
      software to the use of fully automated closed-loop insulin delivery or to usual care for 20
      days, with a 2-4 week washout period between the two interventions.

        1. Closed loop arm Following randomisation, participants in the closed-loop group will
           receive training to cover key aspects of insulin pump use and CGM. Competency on the use
           of study devices will be evaluated Once competent in the use of the study pump and CGM,
           participants will receive training required for safe and effective use of the
           closed-loop system. During a 2-4 hour session participants will operate the system under
           the supervision of the clinical team. Competency on the use of closed-loop system will
           be evaluated. Thereafter, participants are expected to use closed-loop for 20 days
           without supervision or remote monitoring.

           All participants will be provided with 24 hour telephone helpline and will also be given
           written instructions about when to contact clinical team.

        2. Standard therapy (control arm) Participants in the control group will continue with
           standard insulin therapy with blinded CGM for 20 days.

      Study contacts Follow up contacts will be conducted within 24 hours of starting each
      treatment arm and then at weekly intervals thereafter.

      End of study assessments Validated questionnaires evaluating the impact of the technology on
      diabetes management and quality of life will be completed. Participants will resume usual
      care.

      Procedures for safety monitoring during trial Standard operating procedures for monitoring
      and reporting of all adverse events (AE) will be in place, including serious adverse events
      (SAE), serious adverse device effects (SADE).

      A data safety and monitoring board (DSMB) will be informed of all serious adverse events and
      any unanticipated serious adverse device effects that occur during the study and will review
      compiled adverse event data at periodic intervals.

      Criteria for withdrawal of patients on safety grounds

      A participant may terminate participation in the study at any time without necessarily giving
      a reason and without any personal disadvantage. An investigator can stop the participation of
      a subject after consideration of the benefit/risk ratio. Possible reasons are:

        1. Serious adverse events

        2. Significant protocol violation or non-compliance

        3. Failure to satisfy competency assessment

        4. Decision by the investigator, or the Sponsor, that termination is in the participant's
           best medical interest

        5. Pregnancy, planned pregnancy, or breast feeding

        6. Allergic reaction to insulin

      Efforts will be made to retain participants in follow up for the final primary outcome
      assessment even if the intervention is discontinued, unless the investigator believes that it
      will be harmful for the participant to continue in the trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in the target glucose range (5.6 to 10.0 mmol/l)</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Percentage of time spent with sensor glucose readings in the target range from 5.6 to 10.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time spent above target glucose (10.0 mmol/l)</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Both armsPercentage of time spent with sensor glucose readings above target glucose (10.0 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Mean sensor glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in hypoglycaemia (&lt;3.9 mmol/l)</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Percentage of time spent with sensor glucose readings &lt;3.9 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent below target glucose (5.6 mmol/l)</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Percentage of time spent with sensor glucose readings below target glucose (5.6 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of glucose levels</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Standard deviation of glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation of glucose levels</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Coefficient of variation of glucose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent below &lt;3.0 mmol/l</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Percentage of time spent with sensor glucose readings &lt;3.0 mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in significant hyperglycaemia (&gt; 20 mmol/l)</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Percentage of time with glucose levels in significant hyperglycaemia (&gt; 20 mmol/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total, basal and bolus insulin dose</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Average daily total, basal and bolus insulin requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of glucose below 3.5 mmol/l</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Area under the curve of sensor glucose readings below 3.5mmol/l</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of episodes of severe hypoglycaemia</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Safety evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects experiencing severe hypoglycaemia</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Safety evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency and nature of other adverse events or serious adverse events</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Safety evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of time of closed-loop operation</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Utility evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of time of CGM availability</measure>
    <time_frame>20 day intervention period</time_frame>
    <description>Utility evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Average inter-dialytic weight gain</measure>
    <time_frame>20 day intervention period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Closed loop insulin delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unsupervised home use of day and night fully automated closed loop insulin delivery system (CamAPS HX) for 20 days
The CamAPS HX closed-loop system comprises
Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump
Glooko/Diasend cloud upload system to monitor CGM/insulin data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the control arm will continue to follow their current diabetes management plan for the 20 day study period.Participants will be wear a masked continuous glucose monitoring (CGM) system during the 20 day study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CamAPS HX Closed-loop</intervention_name>
    <description>The CamAPS HX closed-loop system comprises
Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)
Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)
An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump
Glooko/Diasend cloud upload system to monitor CGM/insulin data.</description>
    <arm_group_label>Closed loop insulin delivery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiple Daily Insulin Injections (Control)</intervention_name>
    <description>Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)</description>
    <arm_group_label>Standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is age 18 years or over

          -  Diagnosis of type 2 diabetes using standard diagnostic practice

          -  The subject requires maintenance dialysis

          -  The subject requires current treatment with subcutaneous insulin

          -  Screening HbA1c â‰¤ 11% (97mmol/mol) on analysis from local laboratory

          -  Subject is willing to perform regular finger-prick blood glucose monitoring

          -  The subject is literate in English (UK) or German (Switzerland)

          -  The subject is willing to wear study devices 24/7 during intervention arm and follow
             study specific instructions

        Exclusion Criteria:

          -  Physical or psychological condition likely to interfere with the normal conduct of the
             study and interpretation of the study results as judged by the investigator

          -  Known or suspected allergy to insulin

          -  Lack of reliable telephone facility for contact

          -  Pregnancy, planned pregnancy, or breast feeding

          -  Severe visual impairment

          -  Severe hearing impairment

          -  Medically documented allergy towards the adhesive (glue) of plasters or unable to
             tolerate tape adhesive in the area of sensor placement

          -  Serious skin diseases located at places of the body, which potentially are possible to
             be used for localisation of the glucose sensor

          -  Illicit drugs abuse

          -  Prescription drugs abuse

          -  Alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Hovorka, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roman Hovorka, PhD</last_name>
    <phone>+44 (0)1223 762 862</phone>
    <email>rh347@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inselspital, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lia Bally, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lia Bally, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Hovorka, PhD</last_name>
      <email>rh347@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Andrew Fry, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Boughton, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Dr Roman Hovorka</investigator_full_name>
    <investigator_title>Professor of Metabolic Technology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Fully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

